|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adult-to-adult living-donor liver transplantation: The experience of the Université catholique de Louvain显示文摘Background: Liver transplantation is the treatment for end-stage liver diseases and well-selected malignancies. The allograft shortage may be alleviated with living donation. The initial UCLouvain experience of adult living-donor liver transplantation(LDLT) is presented. Methods: A retrospective analysis of 64 adult-to-adult LDLTs performed at our institution between 1998 and 2016 was conducted. The median age of 29(45.3%) females and 35(54.7%) males was 50.2 years(interquartile range, IQR 32.9–57.5). Twenty-two(34.4%) recipients had no portal hypertension. Three(4.7%) patients had a benign and 33(51.6%) a malignant tumor [19(29.7%) hepatocellular cancer, 11(17.2%) secondary cancer and one(1.6%) each hemangioendothelioma, hepatoblastoma and embryonal liver sarcoma]. Median donor and recipient follow-ups were 93 months(IQR 41–159) and 39 months(22–91), respectively. Results: Right and left hemi-livers were implanted in 39(60.9%) and 25(39.1%) cases, respectively. Median weights of right-and left-liver were 810 g(IQR 730–940) and 454 g(IQR 394–534), respectively. Graft-to-recipient weight ratios(GRWRs) were 1.17%(right, IQR 0.98%-1.4%) and 0.77%(left, 0.59%-0.95%). One-and five-year patient survivals were 85% and 71%(right) vs. 84% and 58%(left), respectively. Oneand five-year graft survivals were 74% and 61%(right) vs. 76% and 53%(left), respectively. The patient and graft survival of right and left grafts and of very small( < 0.6%), small(0.6%–0.79%) and large( ≥0.8%) GRWR were similar. Survival of very small grafts was 86% and 86% at 3-and 12-month. No donor died while five(7.8%) developed a Clavien–Dindo complication IIIa, IIIb or IV. Recipient morbidity consisted mainly of biliary and vascular complications; three(4.7%) recipients developed a small-for-size syndrome according to the Kyushu criteria. Conclusions: Adult-to-adult LDLT is a demanding procedure that widens therapeutic possibilities of many hepatobiliary diseases. The donor procedure can be done safely with low morbidity. The recipient operation carries a major morbidity indicating an important learning curve. Shifting the risk from the donor to the recipient, by moving from the larger right-liver to the smaller left-liver grafts, should be further explored as this policy makes donor hepatectomy safer and may stimulate the development of transplant oncology. | Samuele Iesari Milton Eduardo Inostroza Nú?ez Juan Manuel Rico Juri Olga Ciccarelli Eliano Bonaccorsi-Riani Laurent Coubeau Pierre-Fran?ois Laterre Pierre Goffette Chantal De Reyck Beno?t Lengelé Pierre Gianello Jan Lerut | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，2： | 5 |
| 2 | Secondary non-resectable liver tumors:A single-center living-donor and deceased-donor liver transplantation case series显示文摘Background: During the last decades, deceased-donor liver transplantation (DDLT) has gained a place in the therapeutic algorithm of well-selected patients harbouring non-resectable secondary liver tumors. Living-donor LT (LDLT) might represent a valuable means to further expand this indication for LT. Methods: Between 1985 and 2016, twenty-two adults were transplanted because of neuroendocrine ( n = 18, 82%) and colorectal metastases ( n = 4, 18%);50% received DDLT and 50% LDLT. In LDLT, 4 (36%) right and 7 (64%) left grafts were used;the median graft-to-recipient-weight ratios (GRWR) were 1.03%(IQR 0.86%- 1.30%) and 0.59%(IQR 0.51%- 0.91%), respectively. Median post-LT follow-up was 64 months (IQR 17–107) in the DDLT group and 40 months (IQR 35–116) in the LDLT group. DDLT and LDLT recipients were compared in terms of overall survival, graft survival, postoperative complications and recurrence. Results: The 1- and 5-year actuarial patient survivals were 82% and 55% after DDLT, 100% and 100% after LDLT, respectively ( P < 0.01). One- and 5-year actuarial graft survivals were 73% and 36% after DDLT, 91% and 91% after LDLT ( P < 0.01). The outcomes of right or left LDLT were comparable. Donor hepatectomy proved safe, and one donor experienced a Clavien IIIb complication. Bilirubin peak was significantly lower after left hepatectomy compared with that after right hepatectomy [1.3 (IQR 1.2–2.2) vs. 3.3 (IQR 2.3–5.2) mg/dL;P = 0.02]. Conclusions: The more recent LDLT series compared favorably to our DDLT series in the treatment of secondary liver malignancies. The absence of portal hypertension and the use of smaller left grafts make recipient and donor surgeries safe. The safety of the procedures and lack of interference with the scarce allograft pool are expected to lead to a more frequent use of LDLT in the field of transplant oncology. | Jan Lerut Samuele Iesari Gaetan Vandeplas Tiziana Fabbrizio Kevin Ackenine Milton Eduardo Inostroza Nunez Mina Komuta Laurent Coubeau Olga Ciccarelli Eliano Bonaccorsi-Riani | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，5： | 2 |
| 3 | Effect of obstacle size and spacing on the initial stage of flame acceleration in a rough tube显示文摘 | Ciccarelli G Fowler C J Bardon M | 2005 | Shock Waves2005，14，3： | 1 |
| 4 | Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF 显示文摘 | Esumi N Budarf M Ciccarelli L | 1998 | Mamm Genome1998，9，9： | 1 |
| 5 | Construction of synthetic genes using PCR after automated DNA synthesis of their entire top and bottom strands显示文摘 | CICCARELLI R B GUNYUZLU P HUANG J | 1991 | Nucleic Acids Res1991，19，21： | 1 |
| 6 | Toward automatic reconstruction of a highly resolved tree of life 显示文摘 | CICCARELLI F D DOERKS T VON MERING C | 2006 | Science2006，311，： | 1 |
| 7 | Conserved gene structure and genomie linkage for D-dopaehrom tautomerase(DDT)and MIF显示文摘 | Esumi N Budarf M Ciccarelli L | 1998 | Mamm Genome1998，9，9： | 1 |
| 8 | CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia显示文摘 | Ho AW Hatjiharissi E Ciccarelli BT | 2008 | Blood2008，112，12： | 1 |
| 9 | Mechanisms of apoptosis induced by purine nucleosides in astrocytes 显示文摘 | Patrizia DI Sonya K Ciccarelli R | 2002 | Glia2002，38，3： | 1 |
| 10 | Involvement of astrocytes in purine-mediated reparative processes in the brain 显示文摘 | Ciccarelli R Ballerini P Sabatino G | 2001 | Int J Dev Neurosci2001，19，4： | 1 |
| 11 | Fragmentation mechanisms based on single drop steam explosion experiments using flash X-ray radiography显示文摘 | Ciccarelli G Frost D L | 1994 | Nuclear Engineer-ing Design1994，146，： | 1 |
| 12 | Mechanisms of apoptosis induced by purine nucleosides in astrocytes显示文摘 | Di lorio P Kleywegt S Ciccarelli R | 2002 | Glia2002，38，3： | 1 |
| 13 | A new chaotic algorithm for video encryption 显示文摘 | Chiaraluce F Ciccarelli L Gambi E | 2002 | IEEE Transaction on Consumer Electronics2002，48，4： | 1 |
| 14 | Primary malignant tumors of the small bowel显示文摘 | Ciccarelli O Welch JP Kent GG | 2002 | Am J Surg2002，153，4： | 1 |
| 15 | MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma显示文摘 | Marampon F Bossi G Ciccarelli C | 2009 | Mol Cancer Ther2009，8，54： | 1 |
| 16 | Diagnosis and drug therapy of prolactinoma显示文摘 | Ciccarelli E Camanni F | 1996 | Drugs1996，51，6： | 1 |
| 17 | A longitudinal study of abnormalities on MRI and disability from multiple sclerosis显示文摘 | Brex PA Ciccarelli O O'Riordan JI | 2002 | N Engl J Med2002，346，： | 1 |
| 18 | Growth inhibition of human hepatocellular carcinoma cells by overexpression of G-protein-coupled receptor kinase2显示文摘 | Wei Z Hurtt R Ciccarelli M Koch WJ Doria C | 2012 | J Cell Physiol2012，227，6： | 1 |
| 19 | Angiotensin Ⅱ receptor blockers and insulin resistance显示文摘 | Ciccarelli L | | 0，，08： | 1 |
| 20 | Primary malignant tumors of thesmall bowel显示文摘 | Ciccarelli O Welch JP Kent GG | 1987 | Am J Surg1987，153，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员